G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 4.65 EUR -4.12% Market Closed
Market Cap: 232.5m EUR

Profitability Summary

Genfit SA's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Genfit SA

Revenue
45.4m EUR
Cost of Revenue
-2.1m EUR
Gross Profit
43.3m EUR
Operating Expenses
-71.2m EUR
Operating Income
-27.9m EUR
Other Expenses
-10.9m EUR
Net Income
-38.8m EUR

Margins Comparison
Genfit SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
FR
Genfit SA
PAR:GNFT
232.5m EUR
95%
-61%
-85%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
399.6B USD
71%
33%
4%
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
72%
34%
19%
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD
79%
39%
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD
86%
39%
31%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.6B USD
86%
28%
32%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.4B USD
84%
8%
1%
AU
CSL Ltd
ASX:CSL
89.1B AUD
52%
26%
19%
NL
argenx SE
XBRU:ARGX
47.2B EUR
90%
22%
43%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Genfit SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
FR
Genfit SA
PAR:GNFT
232.5m EUR
-52%
-19%
-17%
-28%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
399.6B USD
139%
2%
20%
28%
US
Amgen Inc
NASDAQ:AMGN
177.5B USD
82%
8%
17%
15%
US
Gilead Sciences Inc
NASDAQ:GILD
150.6B USD
41%
14%
25%
19%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.7B USD
22%
16%
23%
25%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.6B USD
15%
12%
11%
12%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.4B USD
33%
1%
8%
-21%
AU
CSL Ltd
ASX:CSL
89.1B AUD
16%
8%
12%
10%
NL
argenx SE
XBRU:ARGX
47.2B EUR
30%
26%
15%
61%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less